Previous 10 | Next 10 |
Gvoke™ Pre-Filled Syringe (PFS) net sales of $1.7 million in Q1 2020 Gvoke HypoPen™ on track for planned launch in July 2020 Initiated programs to ensure easier patient access to GVOKE in the midst of the COVID-19 pandemic Corporate actions taken to conserve ca...
Xeris Pharmaceuticals (NASDAQ: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, recently announced that it will release its first quarter 2020 financial results ...
Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced that the Company will release its first quarte...
Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced it has extended its $0 copay offer for Gvoke™ Pre-F...
Nano cap Xeris Pharmaceuticals (NASDAQ: XERS ) is up 19% premarket on light volume in reaction to results from a Phase 1b study assessing two dose levels of its injectable formulation of diazepam in 20 healthy volunteers. More news on: Xeris Pharmaceuticals, Inc., Healthcare ...
Xeris’ IM diazepam maintains higher concentration over longer time period versus standard of care Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation platforms to develop and commercialize ready-to-use injectable and in...
Xeris Pharmaceuticals Inc. (NASDAQ: XERS) was featured in a recent equity research report published by Mizuho Securities USA LLC. The report reads, “We applied a weighted average valuation methodology (DCF+EV/Sales) to derive our $18PT. Our assumptions include: Launch of the glucagon re...
Gainers: Camber Energy (NYSEMKT: CEI ) +61% . More news on: Camber Energy, Inc., Cancer Genetics, Inc., Micron Solutions, Inc., Stocks on the move, , Read more ...
Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced a limited-time $0 copay offering for commercially eligible...
GVOKE Pre-Filled Syringe (PFS) is available for home delivery through PillPack by Amazon Pharmacy Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable an...
News, Short Squeeze, Breakout and More Instantly...
Xeris Pharmaceuticals Inc. Company Name:
XERS Stock Symbol:
NASDAQ Market:
Xeris Pharmaceuticals Inc. Website:
The Dow Jones index closed higher by over 100 points on Friday. When insiders purchase or sell shares, it indicates their confidence or concern aro...
2024-05-10 10:00:12 ET David Amsellem from Piper Sandler issued a price target of $3.00 for XERS on 2024-05-10 08:29:00. The adjusted price target was set to $3.00. At the time of the announcement, XERS was trading at $1.8469. The overall price target consensus is at $6....
Q1 2024 Total Revenue of $40.6M – up 22% over Q1 2023 Tightening full-year 2024 total revenue guidance to $175M-$200M Ended Q1 with $87.4M in cash, cash equivalents, and short-term investments, lowered borrowing rate of Hayfin debt by 2.05% Entered into a worldwide ...